2. Navratil V., Cvekova S., Slodicka P. et al. Extraintestinal complications of inflammatory bowel diseases. Vnitr Lek. 2021; 67(2): 92–96.

3. Маев И.В., Шелыгин Ю.А., Скалинская М.И. с соавт. Патоморфоз воспалительных заболеваний кишечника. Вестник Российской академии медицинских наук. 2020; 75(1): 27–35. [Maev I.V., Shelygin Yu.A., Skalinskaya M.I. et al. The pathomorphosis of inflammatory bowel diseases. Vestnik Rossiyskoy akademii meditsinskikh nauk = Annals of the Russian Academy of Medical Sciences. 2020; 75(1): 27–35 (In Russ.)]. https://dx.doi.org/10.15690/vramn1219. EDN: FWJIAO.

4. Filimon A.M., Negreanu L., Doca M. et al. Cardiovascular involvement in inflammatory bowel disease: Dangerous liaisons. World J Gastroenterol. 2015; 21(33): 9688–92. https://dx.doi.org/10.3748/wjg.v21.i33.9688.

5. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: A systematic analysis for the global burden of disease study 2016. Lancet. 2017; 390(10100): 1151–210.https://dx.doi.org/10.1016/S0140-6736(17)32152-9.

6. Timmis A., Townsend N., Gale C.P. et al.; European Society of Cardiology. European Society of Cardiology: Cardiovascular disease statistics 2019. Eur Heart J. 2020; 41(1): 12–85. https://dx.doi.org/10.1093/eurheartj/ehz859.

7. Rellecke P., Strauer B.E. [Chronic inflammatory bowel disease and cardiovascular complications. Med Klin (Munich). 2006; 101 Suppl 1: 56–60 (In German)].

8. Lykowska-Szuber L., Rychter A.M, Dudek M. et al. What links an increased cardiovascular risk and inflammatory bowel disease? A Narrative Review. Nutrients. 2021; 13(8): 2661. https://dx.doi.org/10.3390/nu13082661.

9. Czubkowski P., Osiecki M., Szymanska E., Kierkus J. The risk of cardiovascular complications in inflammatory bowel disease. Clin Exp Med. 2020; 20(4): 481–91. https://dx.doi.org/10.1007/s10238-020-00639-y.

10. Roifman I., Sun Y.C., Fedwick J.P. et al. Evidence of endothelial dysfunction in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2009; 7(2): 175–82. https://dx.doi.org/10.1016/j.cgh.2008.10.021.

11. Aloi M., Tromba L., Di Nardo G. et al. Premature subclinical atherosclerosis in pediatric inflammatory bowel disease. J Pediatr. 2012; 161(4): 589–94.e1. https://dx.doi.org/10.1016/j.jpeds.2012.03.043.

12. Kayahan H., Sari I., Cullu N. et al. Evaluation of early atherosclerosis in patients with inflammatory bowel disease. Dig Dis Sci. 2012; 57(8): 2137–43. https://dx.doi.org/10.1007/s10620-012-2148-x.

13. Binion D.G., West G.A., Ina K. et al. Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease. Gastroenterology. 1997; 112(6): 1895–907. https://dx.doi.org/10.1053/gast.1997.v112.pm9178682.

14. van de Wouw J., Sorop O., van Drie R.W.A. et al. Perturbations in myocardial perfusion and oxygen balance in swine with multiple risk factors: A novel model of ischemia and no obstructive coronary artery disease. Basic Res Cardiol. 2020; 115(2) :21.https://dx.doi.org/10.1007/s00395-020-0778-2.

15. Хлынова О.В., Степина Е.А. Особенности состояния сосудистого эндотелия у лиц с тяжелыми формами воспалительных заболеваний кишечника. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018; 28(5): 98–104. [Khlynova O.V., Stepina E.A. Specific features of vascular endothelium in patients with severe forms of inflammatory bowel diseases. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018; 28(5): 98–104 (In Russ.)]. https://dx.doi.org/10.22416/1382-4376-2018-28-5-98-104. EDN: YOCIWD.

16. Степина Е.А., Копосова К.А., Хлынова О.В. с соавт. Маркеры системного воспаления и микроальбуминурия при воспалительных заболеваниях кишечника. Экспериментальная и клиническая гастроэнтерология. 2016; 3: 15–19. [Stepina E.A., Koposova K.A., Khlynova O.V. et al. Systemic inflammation markers and microalbuminuria in inflammatory bowel diseases. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2016; 3: 15–19 (In Russ.)]. EDN: VVIRWP.

17. Zanoli L., Cannavo M., Rastelli S. et al. Arterial stiffness is increased in patients with inflammatory bowel disease. J Hypertens. 2012; 30(9): 1775–81. https://dx.doi.org/10.1097/HJH.0b013e3283568abd.

18. Миронова О.Ю., Исайкина М.А., Хасиева С.А. Атеросклероз и сердечно-сосудистый риск у пациентов с воспалительными заболеваниями кишечника. Терапевтический архив. 2021; 93(12): 1533–1538. [Mironova O.Yu., Isaikina M.A., Khasieva S.A. Аtherosclerosis and cardiovascular risk in patients with inflammatory bowel disease. Terapevticheskiy arkhiv = Therapeutic Archive. 2021; 93(12): 1533–1538 (In Russ.)]. https://dx.doi.org/10.26442/00403660.2021.12.201225. EDN: HJJJXN.

19. Theocharidou E., Gossios T. D., Griva T. et al. Is there an association between inflammatory bowel diseases and carotid intima-media thickness? Preliminary Data. Angiology. 2014; 65(6): 543–50. https://dx.doi.org/10.1177/0003319713489876.

20. D’Angelo A., Mazzola G., Crippa L. et al. Hyperhomocysteinemia and venous thromboembolic disease. Haematologica. 1997; 82(2): 211–19.

21. Lin C.P., Chen Y.H., Leu H.B. et al. Anti-inflammatory strategies for homocysteine-related cardiovascular disease. Front Biosci (Landmark Ed). 2009; 14(10): 3836–45. https://dx.doi.org/10.2741/3492.

22. Oldenburg B., Fijnheer R., van der Griend R. et al. Homocysteine in inflammatory bowel disease: A risk factor for thromboembolic complications. Am J Gastroenterol. 2000; 95(10): 2825–30. https://dx.doi.org/10.1111/j.1572-0241.2000.03193.x.

23. Romagnuolo J., Fedorak R., Dias V.C. et al. Hyperhomocysteinemia and inflammatory bowel disease: Prevalence and predictors in a cross sectional study. Am J Gastroenterol. 2001; 96(7): 2143–49. https://dx.doi.org/10.1111/j.1572-0241.2001.03950.x.

24. Koutroubakis I.E. The relationship between coagulation state and inflammatory bowel disease: current understanding and clinical implications. Expert Rev Clin Immunol. 2015; 11(4): 479–88. https://dx.doi.org/10.1586/1744666X.2015.1019475.

25. Бикбавова Г.Р., Ливзан М.А. Системное воспаление и кардиоваскулярные риски у больных воспалительными заболеваниями кишечника: что необходимо учитывать? Экспериментальная и клиническая гастроэнтерология. 2021; 6: 112–120. [Bikbavova G.B., Livzan M.A. Cardiovascular risks in patients with inflammatory bowel disease: what should be taken into account? Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2021; 6: 112–120 (In Russ.)]. https://dx.doi.org/10.31146/1682-8658-ecg-190-6-112-120. EDN: LILMEV.

26. Hatoum O.A., Binion D.G. The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology. Inflamm Bowel Dis. 2005; 11(3): 304–13. https://dx.doi.org/10.1097/01.mib.0000160772.78951.61.

27. Lam A., Borda I.T., Inwood M.J., Thomson S. Coagulation studies in ulcerative colitis and Crohn’s disease. Gastroenterology, 1975; 68(2): 245–51.

28. Chamouard P., Grunebaum L., Wiesel M.L. et al. Prothrombin fragment 1+2 and thrombin antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 1995; 7(12): 1183–88.https://dx.doi.org/10.1097/00042737-199512000-00010.

29. Кляритская И.Л., Стилиди Е.И., Максимова Е.В., Шахбазиди Г. Внекишечные проявления воспалительных заболеваний кишечника. Крымский терапевтический журнал. 2017; 1: 47–51. [Kliaritskaia I.L., Stilidi E.I., Maksimova E.V., Shakhbazidi G. Extraintestinal manifestations of inflammatory bowel disease. Krymskiy terapevticheskiy zhurnal = Crimean Therapeutic Journal. 2017; 1: 47–51 (In Russ.)]. EDN: XWTYLF.

30. Bernstein C.N., Blanchard J.F., Houston D.S. et al. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: A population-based cohort study. Thromb Haemostasis. 2001; 85(3): 430–34.https://dx.doi.org/10.1111/j.1572-0241.2001.03756.x.

31. Singh S., Singh H., Loftus E.V. Jr, Pardi D.S. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014; 12(3): 382–93.e1: quiz e22. https://dx.doi.org/10.1016/j.cgh.2013.08.023.

32. Theocharidou E., Gossios T.D., Karagiannis A. Are patients with inflammatory bowel diseases at increased risk for cardiovascular disease? Clin Gastroenterol Hepatol. 2014; 12(12): 2134–35. https://dx.doi.org/10.1016/j.cgh.2014.04.004.

33. Shaw L.J. Bugiardini R. Merz C.N. Women and ischemic heart disease: Evolving knowledge. J Am Coll Cardiol. 2009; 54(17): 1561–75. https://dx.doi.org/10.1016/j.jacc.2009.04.098.

34. Cook N.R. Buring J.E. Ridker P.M. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med. 2006; 145(1): 21–29. https://dx.doi.org/10.7326/0003-4819-145-1-200607040-00128.

35. Feng W., Chen G., Cai D. et al. Inflammatory bowel disease and risk of ischemic heart disease: An updated meta-analysis of cohort studies. J Am Heart Assoc. 2017; 6(8): e005892. https://dx.doi.org/10.1161/JAHA.117.005892.

36. Tsai M.S., Lin C.L., Chen H.P. et al. Long-term risk of acute coronary syndrome in patients with inflammatory bowel disease: A 13-year nationwide cohort study in an Asian population. Inflamm Bowel Dis. 2014; 20(3): 502–7.https://dx.doi.org/10.1097/01.MIB.0000441200.10454.4f.

37. Kristensen S.L., Ahlehoff O., Lindhardsen J. et al. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death – a Danish nationwide cohort study. PLoS One. 2013; 8(2): e56944.https://dx.doi.org/10.1371/journal.pone.0056944.

38. Zoller B., Li X., Sundquist J., Sundquist K. Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. PLoS ONE. 2012; 7(3): e33442. https://dx.doi.org/10.1371/journal.pone.0033442.

39. Kappelman M.D., Horvath-Puho E., Sandler R.S. et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: A population-based nationwide study. Gut. 2011;60(7): 937–43. https://dx.doi.org/10.1136/gut.2010.228585.

40. Panhwar M.S., Mansoor E., Al-Kindi S.G. et al. Risk of myocardial infarction in inflammatory bowel disease: A population-based National study. Inflamm Bowel Dis. 2019; 25(6): 1080–87. https://dx.doi.org/10.1093/ibd/izy354.

41. Agca R., Smulders Y., Nurmohamed M. Cardiovascular disease risk in immune-mediated inflammatory diseases: recommendations for clinical practice. Heart. 2022; 108(1): 73–79. https://dx.doi.org/10.1136/heartjnl-2019-316378.

42. Panhwar M.S., Mansoor E., Al-Kindi S.G. et al. Risk of myocardial infarction in inflammatory bowel disease: A population-based National study. Inflamm Bowel Dis. 2019; 25(6): 1080–87. https://dx.doi.org/10.1093/ibd/izy354.